Publications

Filter Publications By:

Binimetinib / Cancer

01/20/2012

Gastrointestinal Cancers Symposium

A Phase 1 Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Biliary Tract Cancer

RS Finn, et al.

Motolimod / VTX-2337

01/15/2012

Clinical Cancer Research

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC

Lu H, Dietsch GN, et al

ARRY-614 / MDS

12/11/2011

American Society of Hematology Annual Meeting

Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes

R. Komrokji, et al.

Filanesib / Multiple Myeloma

12/11/2011

American Society of Hematology Annual Meeting

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma

S. Lonial, M.D. et al.

Filanesib / Multiple Myeloma

12/10/2011

American Society of Hematology Annual Meeting

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

J.J. Shah, MD, et al.

ARRY-797 / LMNA DCM

11/15/2011

Circulation

Inhibition of Site Specific Phosphorylation of Retinoblastoma Protein by a p38 Inhibitor Decreases Apoptosis, Improves Survival and Prevents Cardiomyopathy Caused by a Mutation in LMNA gene

Saqib et al

Ipatasertib / Cancer

11/14/2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues

Y. Yan, et al.

ARRY-380 / Breast Cancer

11/14/2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

ARRY-380, a Selective HER2 Inhibitor: From Drug Design to Clinical Evaluation

S. L. Moulder, et al.

Binimetinib / Cancer

11/14/2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

A Phase 1 Dose-Escalation Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Advanced Solid Tumors

J. Bendell, et al.

Filanesib / Multiple Myeloma

10/18/2011

International Society for the Study of Xenobiotics Conference

An Effective Screening Approach to Assess the Impact of alpha-1 Acid Glycoprotein Binding on the Fraction Unbound of a Drug

K. D. Brown